RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > 2022 > 2 > Recon: SEC, FTC investigating Aduhelm approval and marketing; Doctors and public health group mount

Recon: SEC, FTC investigating Aduhelm approval and marketing; Doctors and public health group mount campaign for Biden’s FDA pick

Posted 07 February 2022 | By Joanne S. Eglovitch 

Recon: SEC, FTC investigating Aduhelm approval and marketing; Doctors and public health group mount campaign for Biden’s FDA pick

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
 
In Focus: US
  • Biogen says FTC, SEC probing Alzheimer's disease drug (Reuters) (Endpoints) (Fierce)
  • In a bid to save Biden’s FDA pick, doctors and public health groups are mounting a rare pressure campaign (STAT)
  • Pfizer's COVID cash pile opens opportunities for deals (Reuters)
  • Teva, Texas strike opioid settlement worth $225 million (Reuters)
  • Breaking with past comments, FDA's Richard Pazdur telegraphs rough road ahead for Lilly's China-developed cancer drug (Endpoints) (STAT)
  • Biden’s top science adviser bullied and demeaned subordinates, according to White House investigation (Politico) (WSJ)
  • After some lengthy delays, Sanofi gets the FDA's OK for a rare disease drug (Endpoints)
  • UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx (Fierce) (Endpoints)
  • Regeneron revenue beats estimates on strong sales of Eylea, COVID therapy (Reuters)
  • Pfizer’s $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies (Fierce)
  • How researchers can get a handle on the monkey shortage for tox studies: FDA explains (Endpoints)
In Focus: International
  • COVID disrupts health services in over 90% of countries -WHO (Reuters)
  • With thousands of jobs on the chopping block, 'nothing's off the table' at Sanofi. What's staying and what's going? (Endpoints)
  • France's Sanofi still sees COVID-19 phase 3 trial completed in first quarter (Reuters)
  • Innovent/Lilly’s Sintilimab, Developed In China, May Be Headed For Troubled US Waters (The Pink Sheet)
  • UK Regulator ‘Optimistic’ About EU Proposals For Northern Ireland Drug Supply (The Pink Sheet)
  • CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase data on C5 inhibitor (Fierce)
  • UK’s CMA Issues £35m In Fines Over Prochlorperazine (The Pink Sheet)
  • India approves Sputnik Light COVID shot for unvaccinated - local manufacturer (Reuters)
  • South African regulator approves Sinopharm COVID vaccine (Reuters)
  • Approval of COVID vaccine made in South Africa could take 3 years, WHO says (Reuters)
  • Nigeria receives 2 million doses of J&J COVID vaccine from EU countries (Reuters)
Coronavirus Pandemic
  • Japan PM Kishida calls for doubling booster shots to 1 mln a day (Reuters)
  • US coronavirus cases are dropping. Other countries are breaking records. (Washington Post)
  • CDC: More vaccinated adults hospitalized with omicron, but fewer admitted to ICU (The Hill)
Pharma & Biotech
  • GSK finds American missed 37M routine vaccinations amid pandemic (Fierce)
  • FDA probes TG Therapeutics’ Ukoniq over potential for elevated death risks 1 year after drug’s approval (Fierce)
  • Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T (Fierce)
  • Endeavor snags $101M to go after Boehringer, Roche in lung scarring – and do some asset shopping (Fierce)
  • Takeda joins Novartis and Merck in $45M funding for Koneksa Health (Fierce)
  • Top 10 most anticipated drug launches of 2022 (Fierce)
  • Pharma’s cyber vulnerabilities run deeper than Merck’s ‘NotPetya’ attack: report (Fierce)
  • Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal (Fierce)
  • Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck’s drug (Fierce)
  • Vanda's gastric drug flops in late-stage test, crashing the biotech's stock (Endpoints)
  • Vas Narasimhan and Severin Schwan each claimed pay packets worth $12M+ for 2021 (Endpoints)
  • Months after Tmunity ground to a halt on clinical hold, cell therapy pioneer Oz Azam is jumping to a stealth startup (Endpoints)
Medtech
  • Ambu scores FDA clearance for single-use gastroscope and touchscreen display (Fierce)
  • Roche partner recalls illegally imported rapid COVID-19 tests from US (MedTech Dive)
  • Procedure volatility, testing uncertainty & FDA delays: Medtech trends in 2022 (MedTech Dive)
Government, Regulatory & Legal
  • Philly, Pittsburgh DAs Lose Bid To Stop Opioid Settlement (Law360)
  • In a victory for medical journals, Pacira loses a libel lawsuit over ‘faulty scientific research’ allegations (STAT)
  • Inside J&J's secret plan to cap litigation payouts to cancer victims (Reuters)
  • In upholding Martin Shkreli's lifetime ban, judge rules any statement he makes about pharma could be a violation (Endpoints) (Reuters)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.

A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe